Sussex Research Collaborator Receives Grant to Develop Glycan-Labelled BODIPY Fluorophores For Use In Glycobiology
Ottawa, Canada, September 5, 2014 – Sussex Research Laboratories Inc. announced today that Professor Hongbin (Tony) Yan of Brock University has received an NSERC Engage grant for a project entitled Labelling glycans with BODIPY fluorophores.
BODIPY fluorophores possess a number of unique properties that have led to their increasing popularity in a wide range of applications. Compared with other commercially available fluorophores such as fluoresceins, rhodamines, and cyanines, BODIPY fluorophores are in general more stable, both chemically and photochemically. Moreover, BODIPY fluorescent properties are relatively pH- and environment-independent, which is a very useful feature in many applications.
The project is expected to combine Sussex Research expertise in the preparation of glycoconjugates and glycans having functionalized linker/spacer systems with the Brock team’s capabilities in BODIPY chemistry. The project is expected to result in a new class of BODIPY fluorophore functionalized carbohydrate-based products.for use in the fields of molecular biology and glycobiology.
According to Brady Clark, President & CEO of Sussex Research, “As industrial partner on the project, Sussex Research is very pleased to support Professor Yan and his research team. The Yan laboratory are experts in BODIPY chemistry with a proven track record of working with BODIPY. This collaboration will extend the novel product portfolio of Sussex Research and make BODIPY-labelled glycans available to researchers worldwide.”
About Sussex Research: As a leading specialist in glycodesign and the synthesis of complex carbohydrates, Sussex Research excels at the discovery and development of molecules that explore and exploit glycobiology. Sussex Research excels in the design, synthesis and characterization of molecules that incorporate glycotechnology. Our unique product portfolio and carbohydrate synthesis capabilities enable researchers across a variety of scientific disciplines to readily explore and exploit glycobiology in order to enhance the therapeutic potential of small molecules, peptides, proteins, lipids and oligonucleotides. For more information visit www.sussex-research.com.
Pharmaceutical Technology Interviews Sussex Research CEO, Dr. Brady Clark, on the “Role of NMR and Mass Spectroscopy in Glycan Analysis.”
Ottawa, Canada, January 2, 2014 – Pharmaceutical Technology recently interviewed Sussex Research scientists, including Dr. Brady Clark, on the role of Nuclear Magnetic Resonance Spectroscopy (NMR) and Mass Spectrometry (MS) in Glycan Synthesis and Analysis. Sussex Research is a well known specialist in carbohydrate synthesis and glycodesign with an established international reputation. As discussed in the interview, NMR and MS are vital to successful development of glycosylation in syntheses of carbohydrate-based molecules and glycans. While NMR analysis provides crucial structural information of synthesized glycans that cannot be determined in any other way, MS analysis confirms molecular weight of target synthons. In bioanalytical analyses, LC-MS/MS is ideal for quantitation of free sugars in biological matrices.
To read the full article, you are directed to PharmaTech.com (http://www.pharmtech.com/role-nmr-and-mass-spectroscopy-glycan-analysis).
About Sussex Research: As a leading specialist in glycodesign and the synthesis of complex carbohydrates, Sussex Research excels at the discovery and development of molecules that explore and exploit glycobiology. Sussex Research excels in the design, synthesis and characterization of molecules that incorporate glycotechnology. Our unique product portfolio and carbohydrate synthesis capabilities enable researchers across a variety of scientific disciplines to readily explore and exploit glycobiology in order to enhance the therapeutic potential of small molecules, peptides, proteins, lipids and oligonucleotides. For more information visit www.sussex-research.com.
Sussex Research Presents Data on “Post Translationally Modified Cosmeceutical Actives” at the Society for Cosmetic Chemists in New York.
New York, December 12, 2013 – Sussex Research scientists gave the first glimpse into the Company’s promising research & development program on carbohydrate-based anti-aging actives. Sussex Research scientists presented the latest results on the Company’s anti-aging carbohydrate-based molecules at the annual Society for Cosmetic Chemists in New York. The poster, entitled “Post Translationally Modified Cosmeceutical Actives,” was extremely well received.
About Sussex Research: As a leading specialist in glycodesign and the synthesis of complex carbohydrates, Sussex Research excels at the discovery and development of molecules that explore and exploit glycobiology. Sussex Research excels in the design, synthesis and characterization of molecules that incorporate glycotechnology. Our unique product portfolio and carbohydrate synthesis capabilities enable researchers across a variety of scientific disciplines to readily explore and exploit glycobiology in order to enhance the therapeutic potential of small molecules, peptides, proteins, lipids and oligonucleotides. For more information visit www.sussex-research.com.
SUSSEX RESEARCH COLLABORATOR RECEIVES NSERC GRANT TO IMPROVE THE MANUFACTURE OF PSEUDAMINIC ACID
Ottawa, Canada, January 17, 2012 – Sussex Research Laboratories Inc. announced today that Professor Christopher N. Boddy of the University of Ottawa has received an NSERC Engage grant for a project entitled Development of a process for the manufacture of pseudaminic acid.
Pseudaminic acid, a sialic acid (neuraminic acid) analogue, represents a promising new class of bacterial sugars with relevance in medicine and biology. Pseudaminic acid containing glycoconjugates are thought to influence pathogenesis through bacterial adhesion, invasion, and immune evasion, and are associated with bacterial cell surface structures such as lipopolysaccharide, capsular polysaccharide, pili and flagella. However, there is no cost-effective method available for the production of this rare sugar.
According to Brady Clark, President & CEO of Sussex Research, “As industrial partner on the project, Sussex Research is very pleased to support Professor Boddy and his research team. The Boddy laboratory are experts in metabolic engineering and have a track record of developing manufacturing processes at the research level, including the development of a commercial fermentation-based process for the production of sialic acid. This collaboration will extend the ability of Sussex Research to make pseudaminic acid available in larger quantities and at reasonable cost to researchers worldwide.”
Development of a fermentation-based process for the manufacture of pseudaminic acid requires metabolic engineering to optimize the production strain and development of an efficient low cost isolation procedure. The Boddy group has been and will continue to work in collaboration with Ian Schoenhofen of the National Research Council (NRC) of Canada, who previously developed the in vitro enzymatic methodology for pseudaminic acid production at milligram scales.
About Sussex Research: Sussex Research is a well known specialist in carbohydrate synthesis and associated methodology development. As a carbohydrate-enabling company with an established international reputation, Sussex Research excels in the design, synthesis and characterization of carbohydrate-based molecules. The company’s unique product portfolio and custom synthesis service enables researchers across a wide variety of scientific research disciplines to readily explore and exploit carbohydrates and carbohydrate modified molecules such as glycoamino acids, glycopeptides, oligosaccharides, special carbohydrate linker/spacer systems and other glycoconjugates in numerous and diverse applications. For more information visit www.sussex-research.com.
SUSSEX RESEARCH LABORATORIES APPOINTS WAKO CHEMICAL INDUSTRIES AS A DISTRIBUTOR FOR ITS CARBOHYDRATE-BASED PRODUCTS & SERVICES IN JAPAN
Ottawa, Canada, May 25, 2010 – Sussex Research Laboratories Inc. has appointed Wako Pure Chemical Industries (Osaka, Japan) as a non-exclusive distributor of Sussex’s complete line of carbohydrate-based reagents (glycoreagents) in Japan. Sussex Research develops and manufactures sophisticated carbohydrate-based molecules for advanced academic research as well as for research & development in the pharmaceutical and biotechnology industries.
Under the new distribution agreement, Sussex glycoreagents are to be marketed under the Sussex Research label and sold, in research quantities, via Wako’s catalogue, sub-distributors and dealer network throughout Japan.
According to Brady Clark, Ph.D., President of Sussex Research, “We are very pleased to be working with Wako, which is renowned for its high purity chemical reagents. We perceive Wako as the leader in Japan for the provision of premium quality research reagents. Scientists in Japan are highly recognized for contributions in glycoscience. This collaboration will extend our ability to make these important glycoreagents including glycoamino acids, glycopeptides, oligosaccharides, PEGylated Glycosides and other unique carbohydrate-based molecules and glycoconjugates available to researchers in Japan.”
About Sussex Research: Sussex Research is a well known specialist in carbohydrate synthesis with an established international reputation. As a carbohydrate-enabling company, Sussex Research excels in the design, synthesis and characterization of carbohydrate-based molecules. The company’s unique product portfolio and custom synthesis service enables researchers across a variety of scientific disciplines to readily explore and exploit carbohydrates and carbohydrate modified molecules such as glycoamino acids, glycopeptides, oligosaccharides, special carbohydrate linker/spacer systems and other glycoconjugates in numerous and diverse applications.
Sussex Research Introduces Unique Sialic Acid-like Pseudaminic Acid Products for Research into Infectious Diseases
Ottawa, Canada, June 25, 2007 – Sussex Research, a leader in advanced glycosylation chemistry and carbohydrate synthesis, today announced that it now manufactures the rare bacterial saccharide, Pseudaminic Acid, along with its nucleotide activated form, CMP-Pseudaminic Acid. These unique saccharides are currently available commercially to researchers worldwide.
Pseudaminic Acid (Pse) (5,7-diacetamido-3,5,7,9-tetradeoxy-L-glycero- -L-manno-nonulosonic acid) is a sialic acid-like, nine-carbon saccharide that was first identified in the lipopolysaccharides (LPS) of Pseudomonas aeruginosa in 1984. The sugar modification has since been observed in several other organisms including the gastrointestinal pathogens Helicobacter pylori and Campylobacter jejuni. The Pse saccharides are thought to influence pathogenesis through bacterial adhesion, invasion, and immune evasion. Pseudaminic Acid has been found in Gram-negative bacterial cell-surface glycoconjugates, such as LPS, capsular polysaccharide, pili and flagella, all of which are important for pathogenesis.
Pseudaminic Acid is unique to bacteria. Many of the bacteria with which Pse has been identified, such as H. Pylori, are associated with serious gastrointestinal diseases that afflict millions of people worldwide. Because of this, its biosynthetic pathway offers potential as a novel therapeutic target and for future small molecule inhibitor screening and design.
“As a carbohydrate synthesis specialist, the Sussex mandate is to help researchers explore and exploit glycobiology. By making Pseudaminic Acid and its derivative available commercially, Sussex will help advance studies on bacteria that contain this modification,” said Dr. Brady Clark, President of Sussex Research. “Research with these products may eventually lead to alternative treatments for those suffering from infectious diseases where Pseudaminic Acid plays a role in their pathogenesis. We are delighted to make these important sugars available to researchers.”
About Sussex Research:
Sussex Research excels in the design, development and manufacture of novel molecules that incorporate glycotechnology. Sussex carbohydrate-based products and services enable researchers to explore and exploit glycobiology via facile introduction of carbohydrate recognition elements in biological molecules such as glycopeptides. The Sussex portfolio of advanced glycosylation products and carbohydrate building blocks enables assembly of oligosaccharides, glycoconjugates and carbohydrate-enhanced molecules. Sussex expertise and custom carbohydrate manufacturing capabilities advance external collaborations in drug discovery, therapeutic development and vaccine design. Sussex Research is the resource for glycosylation and carbohydrate synthesis. For more information, please visit www.sussex-research.com.
For Further Information Contact:
Sussex Research
Brady Clark, Ph.D.
Phone: 613-993-4402
Fax: 613-949-5993
bclark@sussex-research.com
www.sussex-research.com
Sussex Research and NRC Institute for Biological Sciences Form Glycobiology Product Research and Development Agreement
Ottawa, Canada, November 2005 – Sussex Research Laboratories Inc. (Sussex) and the National Research Council (NRC) of Canada’s Institute for Biological Sciences (NRC-IBS) announced today the formation of a strategic research and development agreement designed to advance certain technologies that offer unique opportunities to exploit carbohydrate-based molecules for drug discovery.
Sussex Research is expanding its glycoproducts commercialization efforts in the area of synthetic oligosaccharides and glycoconjugates by forging a strategic alliance with NRC-IBS. The company will collaborate directly with Dr. Dennis Whitfield of the Glycoconjugates and Tumour Immunology Group at NRC-IBS. Dr. Whitfield is a leader in the development of innovative approaches to carbohydrate-based synthesis. The Whitfield lab focuses on design and development of novel approaches to the synthesis of oligosaccharides for use in the development of carbohydrate-based vaccines and glycotherapeutics.
A major objective of the NRC-Sussex agreement is development of new methodologies suitable for synthesizing specific glycoforms for glycoconjugation of biological molecules. Initial focus is on synthetic strategies for glycosylated amino acids and glycopeptides for use in the preparation and subsequent clinical testing of synthetic vaccines, glycosylated peptides and proteins.
ABOUT THE NRC INSTITUTE FOR BIOLOGICAL SCIENCES: The NRC Institute for Biological Sciences in Ottawa is a team of leading life sciences researchers who are committed to making breakthrough discoveries in immunochemistry and neurobiology and moving subsequent technologies into the marketplace.
ABOUT SUSSEX RESEARCH: Sussex Research assists our pharmaceutical, biotechnology and research partners in drug discovery and development through provision of a portfolio of carbohydrate-enabling products and carbohydrate synthesis solutions for development of molecules that incorporate glycotechnology. Carbohydrates play important roles in biological systems ranging from increasing bioavailability, stability and solubility of biological molecules to enhanced target resolution and extended in vivo half-lives. Sussex products and services enable researchers to explore and exploit glycobiology through facile introduction of carbohydrate recognition elements. Sussex products and custom synthesis services may result in improved therapeutic value generation, extension of product franchises as well as creation of new product pipelines and breakthrough therapeutics for our partners. Visit sussex-research.com for more information.
For more information, contact:
K. Brady Clark, Ph.D.
President
Tel: (613) 993-4402
Fax: (613) 949-5993
Sussex Research Takes Occupancy in New NRC Industry Partnership Facility
Ottawa, Canada, April 2003 – Sussex Research Laboratories Inc. (Sussex) announced that it is one of six technology-based companies to take occupancy in the new National Research Council (NRC) of Canada’s Industry Partnership Facility (IPF) located at NRC’s flagship site in Ottawa. The IPF exists to foster and assist companies commercializing NRC technologies or expertise, thereby providing economic gain to Canada, particularly to the National Capital Region. The incubating companies also occupy other offices and laboratories throughout the site. The site is also home to the NRC Steacie Institute for Molecular Sciences (NRC-SIMS), the NRC Institute for Biological Sciences (NRC-IBS), the Canadian Space Agency and some NRC executive offices.
NRC is establishing a network of Industry Partnership Facilities (IPFs) at its research institutes across the country to accelerate innovation, commercialization and to foster the growth of technology clusters all across Canada. By locating at an NRC-IPF, small and medium sized enterprises (SMEs) gain access to world-class research facilities and expertise, national and international networks, as well as business intelligence and knowledge dissemination resources.
ABOUT SUSSEX RESEARCH: Sussex Research is a carbohydrate enabling company whose innovative syntheses allow our pharmaceutical and biotechnology partners to exploit the unique properties associated with carbohydrate-based molecules for a number of biomedical applications including glycotherapeutic and glycoconjugate vaccine development, therapeutic enhancement, glycopeptide synthesis and drug delivery. For additional information on Sussex Research please visit our website at www.sussex-research.com.
For more information, contact:
K. Brady Clark, Ph.D.
President
Tel: (613) 993-4402
Fax: (613) 949-5993
